Anne Altmeyer

CEO and Independent Board Director | Multiple Companies

Anne Altmeyer is a biotech CEO and independent board director with 30 years of leadership experience across biotechnology and global pharmaceutical organizations, with expertise in immunology, oncology, and hematology. Most recently, she served as President, CEO, and Board Member of TigaTx, a preclinical company developing an IgA-based neutrophil engager platform, which she led from early-stage development through its acquisition by Epsilogen Ltd. — raising more than $45 million in dilutive and non-dilutive financing (including funding from ARPA-H), building U.S. operations, recruiting the executive team, and advancing the lead program toward Investigational New Drug (IND)-enabling readiness. She previously served as Chief Business Officer at Sigilon Therapeutics and Adicet Bio. Earlier in her career, she held global business development and negotiation leadership roles at Novartis and Baxalta, where she led oncology, immunology, hematology, companion diagnostics, and gene therapy transactions. Across these roles, she closed transactions totaling more than $3B in disclosed deal value. She led cross-functional drug development teams as a Global Project Leader at Novartis and as a project manager at Merck & Co. Anne is an Independent Board Director of Corbus Pharmaceuticals, where she chairs the Governance & Nominating Committee, and of 20BIO, a stealth-stage biotech. Anne is a member of the CEO Sisterhood and co-chairs the AI Committee of the CEO Forum. She holds a PhD in Immunology from the University Louis Pasteur (Strasbourg, France), an MBA from Rutgers, and an MPH from UMDNJ–Robert Wood Johnson Medical School.